Sigma Healthcare Ltd (ASX: SIG) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Sigma Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$656.75 million
P/E Ratio
10.67
Dividend Yield
1.59%
Shares Outstanding
1.06 billion
Earnings per share
0.059
Dividend per share
0.01
Year To Date Return
4.07%
Earnings Yield
9.37%
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Sigma Healthcare Ltd (ASX: SIG)
Latest News
Healthcare Shares
Here’s why Respiri (ASX:RSH) share price is up 10% today
Healthcare Shares
What’s been happening with the Sigma (ASX:SIG) share price?
Share Fallers
Sigma (ASX:SIG) share price tumbles after CEO resigns
Share Gainers
Why Kathmandu, Pushpay, Sigma, & Vulcan shares are storming higher
Share Gainers
Sigma (ASX:SIG) share price up 7% after doubling full year profits
Share Market News
Is Chemist Warehouse set to become the biggest ASX IPO in 7 years?
Share Gainers
Why Argosy Minerals, Sigma, Vocus, & Zip shares are charging higher
Share Gainers
Here’s why the Sigma (ASX:SIG) share price is surging 6% higher
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 06 Apr 2021 | $0.0100 | 100.00% | Final | 21 Apr 2021 |
| 19 Sep 2019 | $0.0100 | 100.00% | Interim | 04 Oct 2019 |
| 03 Apr 2019 | $0.0200 | 100.00% | Final | 29 Apr 2019 |
| 12 Oct 2018 | $0.0150 | 100.00% | Interim | 29 Oct 2018 |
| 05 Apr 2018 | $0.0250 | 100.00% | Final | 20 Apr 2018 |
| 19 Sep 2017 | $0.0250 | 100.00% | Interim | 05 Oct 2017 |
| 06 Apr 2017 | $0.0300 | 100.00% | Final | 21 Apr 2017 |
| 20 Sep 2016 | $0.0250 | 100.00% | Interim | 03 Oct 2016 |
| 06 Apr 2016 | $0.0300 | 100.00% | Final | 21 Apr 2016 |
| 23 Sep 2015 | $0.0200 | 100.00% | 07 Oct 2015 | |
| 31 Mar 2015 | $0.0100 | 100.00% | 16 Apr 2015 | |
| 31 Mar 2015 | $0.0200 | 100.00% | 16 Apr 2015 | |
| 03 Apr 2014 | $0.0200 | 100.00% | Final | 30 Apr 2014 |
| 21 Sep 2012 | $0.0200 | 100.00% | Interim | 26 Oct 2012 |
| 05 Apr 2011 | $0.1500 | 100.00% | Special Cash | 11 May 2011 |
| 16 Oct 2009 | $0.0300 | 100.00% | Interim | 13 Nov 2009 |
| 31 Mar 2009 | $0.0400 | 100.00% | Final | 07 May 2009 |
SIG ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Sigma Healthcare Ltd
Sigma Healthcare is an Australian pharmaceutical distributor, wholesaler and pharmacy franchisor. The revenue growth prospects and returns of pharmaceutical distribution are subdued due to ongoing Pharmaceutical Benefits Scheme, or PBS, price reform, and regulated wholesale gross margins being capped at 7% for community pharmacy and 10% for hospitals. As a result, Sigma and its competitors, EBOS and API, are seeking to expand into unregulated revenue streams. In addition, pharmacy ownership is restricted to pharmacists, thereby excluding direct corporate ownership and requiring exposure via a franchise business model.
SIG Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 16 Sep 2021 | $0.62 | $-0.01 | -1.59% | 965,002 | $0.63 | $0.63 | $0.62 |
| 15 Sep 2021 | $0.63 | $0.00 | 0.00% | 539,629 | $0.63 | $0.63 | $0.62 |
| 14 Sep 2021 | $0.63 | $0.00 | 0.00% | 968,198 | $0.64 | $0.64 | $0.62 |
| 13 Sep 2021 | $0.63 | $-0.01 | -1.56% | 989,819 | $0.65 | $0.65 | $0.62 |
| 10 Sep 2021 | $0.64 | $-0.01 | -1.54% | 562,942 | $0.65 | $0.65 | $0.63 |
| 09 Sep 2021 | $0.65 | $0.00 | 0.00% | 575,712 | $0.65 | $0.65 | $0.64 |
| 08 Sep 2021 | $0.65 | $0.00 | 0.00% | 567,899 | $0.65 | $0.65 | $0.64 |
| 07 Sep 2021 | $0.65 | $0.00 | 0.00% | 223,813 | $0.64 | $0.65 | $0.64 |
| 06 Sep 2021 | $0.65 | $0.01 | 1.56% | 509,210 | $0.64 | $0.65 | $0.63 |
| 03 Sep 2021 | $0.64 | $0.02 | 3.23% | 441,753 | $0.63 | $0.64 | $0.62 |
| 02 Sep 2021 | $0.62 | $0.00 | 0.00% | 439,209 | $0.63 | $0.63 | $0.62 |
| 01 Sep 2021 | $0.62 | $-0.03 | -4.65% | 970,741 | $0.64 | $0.64 | $0.62 |
| 31 Aug 2021 | $0.65 | $0.01 | 1.57% | 1,013,613 | $0.64 | $0.66 | $0.63 |
| 30 Aug 2021 | $0.64 | $0.02 | 3.23% | 996,712 | $0.63 | $0.64 | $0.62 |
| 27 Aug 2021 | $0.62 | $-0.02 | -3.15% | 473,487 | $0.64 | $0.64 | $0.62 |
| 26 Aug 2021 | $0.64 | $0.01 | 1.59% | 312,708 | $0.64 | $0.64 | $0.62 |
| 25 Aug 2021 | $0.63 | $-0.01 | -1.56% | 321,370 | $0.64 | $0.64 | $0.63 |
| 24 Aug 2021 | $0.64 | $0.00 | 0.00% | 664,840 | $0.64 | $0.65 | $0.63 |
| 23 Aug 2021 | $0.64 | $0.02 | 3.20% | 408,048 | $0.63 | $0.64 | $0.63 |
| 20 Aug 2021 | $0.63 | $-0.02 | -3.13% | 599,962 | $0.62 | $0.65 | $0.62 |
| 19 Aug 2021 | $0.64 | $0.02 | 3.23% | 854,906 | $0.63 | $0.64 | $0.62 |
| 18 Aug 2021 | $0.62 | $-0.01 | -1.59% | 998,438 | $0.63 | $0.64 | $0.62 |
| 17 Aug 2021 | $0.63 | $0.01 | 1.60% | 595,368 | $0.63 | $0.64 | $0.63 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 06 Jul 2021 | Kathryn (Kate) Spargo | Buy | 8 | $5,101 |
Directors' share plan.
|
| 06 Jul 2021 | Raymond Gunston | Buy | 17 | $10,607 |
Directors' share plan.
|
| 06 Jul 2021 | David Manuel | Buy | 9 | $5,820 |
Directors' share plan.
|
| 06 Jul 2021 | Christine Bartlett | Buy | 9 | $5,641 |
Directors' share plan.
|
| 06 Jul 2021 | Michael Sammells | Buy | 9 | $6,000 |
Directors' share plan.
|
| 31 Mar 2021 | Michael Sammells | Buy | 8 | $6,000 |
Directors' share plan.
|
| 31 Mar 2021 | Christine Bartlett | Buy | 8 | $5,641 |
Directors' share plan.
|
| 31 Mar 2021 | David Manuel | Buy | 8 | $5,820 |
Directors' share plan.
|
| 31 Mar 2021 | Kathryn (Kate) Spargo | Buy | 7 | $5,101 |
Directors' share plan.
|
| 31 Mar 2021 | David Bayes | Buy | 7 | $4,922 |
Directors' share plan.
|
| 31 Mar 2021 | Raymond Gunston | Buy | 15 | $10,607 |
Directors' share plan.
|
| 31 Mar 2021 | Mark Hooper | Buy | 590 | $401,582 |
Conversion of securities.
|
| 31 Mar 2021 | Mark Hooper | Exercise | 590 | $401,582 |
Conversion of securities. 1,402,094 - performance rights
|
| 25 Mar 2021 | Mark Hooper | Cancelled | 147 | $102,610 |
Cancellation of securities. 1,992,657 - Performance rights
|
| 25 Mar 2021 | Mark Hooper | Cancelled | 8 | $5,568,073 |
Cancellation of securities.
|
| 16 Dec 2020 | Kathryn (Kate) Spargo | Buy | 8 | $5,282 |
Directors' share plan.
|
| 16 Dec 2020 | Raymond Gunston | Buy | 15 | $9,073 |
Directors' share plan.
|
| 16 Dec 2020 | David Bayes | Buy | 8 | $4,922 |
Directors' share plan.
|
| 16 Dec 2020 | David Manuel | Buy | 9 | $5,581 |
Directors' share plan.
|
| 16 Dec 2020 | Christine Bartlett | Buy | 12 | $7,296 |
Directors' share plan.
|
| 16 Dec 2020 | Michael Sammells | Buy | 9 | $5,941 |
Directors' share plan.
|
| 27 Oct 2020 | Mark Hooper | Buy | 250 | $135,148 |
On-market trade.
|
| 30 Sep 2020 | Kathryn (Kate) Spargo | Buy | 8 | $5,102 |
Directors' share plan.
|
| 30 Sep 2020 | Mark Hooper | Buy | 250 | $140,127 |
On-market trade.
|
| 30 Sep 2020 | David Bayes | Buy | 8 | $4,922 |
Directors' share plan.
|
| 30 Sep 2020 | Raymond Gunston | Buy | 18 | $10,607 |
Directors' share plan.
|
| 30 Sep 2020 | Michael Sammells | Buy | 10 | $6,000 |
Directors' share plan.
|
| 30 Sep 2020 | Christine Bartlett | Buy | 9 | $5,641 |
Directors' share plan.
|
| 30 Sep 2020 | David Manuel | Buy | 10 | $5,820 |
Directors' share plan.
|
| 22 Sep 2020 | Mark Hooper | Buy | 500 | $294,476 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Mark Robert Hooper | Chief Executive OfficerManaging Director | Aug 2010 |
Mr Hooper has a range of experience in finance, commercial and operational matters primarily in the mining and pharmaceutical industries. Mr Hooper is a former Chief Financial Officer and Executive Director of PaperlinX Limited. From 2006 to 2008 Mr Hooper was the Chief Financial Officer and Chief Operating Officer for the Pharmacy and Consumer business for Symbion Health Limited. Prior to that he was Chief Financial Officer of Sigma from 2001 to 2006.
|
| Ms Kathryn (Kate) Dianne Spargo | Non-Executive Director | Dec 2015 |
Ms Spargo has gained business experience as both an adviser, having worked in private practice and government, and as a director of listed and unlisted companies. Ms Spargo is currently Non-Executive Director at Sonic Healthcare Limited, Adairs Limited, and CIMIC Ltd. Ms Spargo has held as Non-Executive Director in Xenith IP Ltd and Fletcher Building Limited. In addition, Ms Spargo's current positions in unlisted companies include Chairman of CoInvest and Director at the Geelong Football Club and Future Fuels Cooperative Research Centre. She is a Member of Risk Management Committee.
|
| Mr Raymond Mark Gunston | Non-Executive DirectorNon-Executive Chairman | Jul 2010 |
Mr Gunston is a Non-Executive Director and Chairman of the Board of Hotel Property Investments Limited. He has over 40 years of corporate and financial services experience in the public and private sectors, specialising in finance, treasury, mergers and acquisitions, and accounting. He is a former Chief Financial Officer of Tatts Group Limited, and of the Australian Football League, a former Director of many of the Tatts Group's subsidiary and associate companies, and the former Interim CEO for the Essendon AFL Football Club. Mr Gunston is currently Chairman of AFL Stadia Pty. Ltd. (Marvel Stadium).
|
| Mr David Gerald Manuel | Non-Executive Director | Oct 2009 |
Mr Manuel has an participant in industry affairs with a special interest in cognitive services such as opiate dependency treatments, compounding, medical technology and aged care pharmacy services. Mr Manuel is a Director of Alchemy Healthcare Pty Ltd, Black Swan Healthcare Ltd, and Elements Health Care Pty Ltd. He is a current Western Australian representative on the Amcal Guardian National Council (AGNC) and a current Branch Committee Member of The Pharmacy Guild of Australia (WA Branch). He is a member of the People and the Risk Management Committee.
|
| Ms Christine Nildra Bartlett | Non-Executive Director | Mar 2016 |
Ms Bartlett as an experienced CEO and senior executive has commercial expertise, with a focus in areas of financial discipline, risk management, innovation, technology, and strategy execution. Ms Bartlett's current directorships in listed entities include Non-Executive Director at Mirvac Group and Reliance Worldwide Corporation Ltd. Ms Bartlett resigned as a Director of GBST Ltd in November 2019. She is a Chair of Remuneration Committee.
|
| Mr Michael Sammells | Non-Executive Director | Feb 2020 |
Mr Sammells is currently a NonExecutive Director at AMP. Mr Sammells has 35 years of experience in finance, corporate services, and has held operational roles with expertise in finance, accounting, treasury, investor relations, capital developments, mergers and acquisitions and IPOs. Mr Sammells is a former Chief Financial Officer of Healthscope Limited and Medibank Private. He is a Chair of Risk Management Committee.
|
| Mr Peter Robert Patterson | Company Secretary | Jul 2021 |
-
|
| J Pearson | Chief Financial Officer |
-
|
|
| Peter Robert Patterson | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 216,547,436 | 20.44% |
| Citicorp Nominees Pty Limited | 185,269,988 | 17.49% |
| J P Morgan Nominees Australia Pty Limited | 139,637,946 | 13.18% |
| Pacific Custodians Pty Limited | 56,376,468 | 5.32% |
| National Nominees Limited | 54,469,536 | 5.14% |
| BNP Paribas Nominees Pty Ltd | 27,903,771 | 2.63% |
| HSBC Custody Nominees (Australia) Limited i | 24,763,999 | 2.34% |
| Sigma Employee Share Admin P/L | 16,555,615 | 1.56% |
| Mr Mark Robert Hooper | 11,860,636 | 1.12% |
| BNP Paribas Noms Pty Ltd | 10,504,240 | 0.99% |
| Jeffrey Sells | 3,602,441 | 0.34% |
| BNP Paribas Nominees Pty Ltd Six Sis Ltd | 2,777,953 | 0.26% |
| Etiam Pty Limited | 2,415,594 | 0.23% |
| Netwealth Investments Limited | 2,090,029 | 0.20% |
| Nabru Nominees Pty Limited | 1,500,000 | 0.14% |
| Mr Peter Urban | 1,438,262 | 0.14% |
| Brian Charles Cannon & Rosalie Cannon | 1,330,500 | 0.13% |
| Neweconomy Com Au Nominees Pty Limited | 1,215,726 | 0.11% |
| Mrs Pamela Ann Royle | 1,126,606 | 0.11% |
| Leithner & Company Pty Ltd | 1,075,000 | 0.10% |